{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:19:16Z","timestamp":1794745156994,"version":"4.9.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K07292"],"award-info":[{"award-number":["JP20K07292"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26K08571"],"award-info":[{"award-number":["JP26K08571"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K09855"],"award-info":[{"award-number":["JP24K09855"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K10047"],"award-info":[{"award-number":["JP24K10047"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008673","name":"Yasuda Memorial Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119905","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:24:22Z","timestamp":1790238262000},"page":"119905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["OSU-03012 mitigates pulmonary fibrosis by targeting ECM proteins via suppression of S6K-mediated translation and acceleration of MMP-driven clearance"],"prefix":"10.1016","volume":"204","author":[{"given":"Kohei","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7722-0843","authenticated-orcid":false,"given":"Masaki","family":"Arioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ishikane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-4432","authenticated-orcid":false,"given":"Kazuhiro","family":"Yatera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Takahashi-Yanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119905_bib1","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119905_bib2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119905_bib3","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119905_bib4","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119905_bib5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00005","article-title":"The clinical course of patients with idiopathic pulmonary fibrosis","volume":"142","author":"Martinez","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2026.119905_bib6","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119905_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2014.00123","article-title":"Fibroblasts in fibrosis: novel roles and mediators","volume":"5","author":"Kendall","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119905_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1242\/dmm.012062","article-title":"Diverse functions of matrix metalloproteinases during fibrosis","volume":"7","author":"Giannandrea","year":"2014","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.biopha.2026.119905_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-018-07858-8","article-title":"The mTORC1\/4E-BP1 axis represents a critical signaling node during fibrogenesis","volume":"10","author":"Woodcock","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119905_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123914","article-title":"Celecoxib inhibits skin fibrosis via suppressing adipocyte progenitor-myofibroblast transdifferentiation by attenuating the YAP\/TAZ signaling pathway","volume":"379","author":"Arioka","year":"2025","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119905_bib11","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/HJH.0000000000002728","article-title":"Cardiac and renal protective effects of 2,5-dimethylcelecoxib in angiotensin II and high-salt-induced hypertension model mice","volume":"39","author":"Yamamoto","year":"2021","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2026.119905_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bcp.2019.06.018","article-title":"2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation","volume":"168","author":"Morishige","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119905_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jphs.2024.01.001","article-title":"2,5-Dimethyl-celecoxib induces early termination of inflammatory responses by transient macrophage accumulation and inhibits the progression of cardiac remodeling in a mouse model of cryoinjury-induced myocardial infarction","volume":"154","author":"Kishigami","year":"2024","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2026.119905_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114950","article-title":"2,5-Dimethylcelecoxib attenuates cardiac fibrosis caused by cryoinjury-induced myocardial infarction by suppressing the fibroblast-to-myofibroblast transformation via inhibition of the TGF-\u03b2 signaling pathway","volume":"197","author":"Ikushima","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119905_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.111.179325","article-title":"Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model","volume":"338","author":"Fan","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119905_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/hr.2016.122","article-title":"2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation","volume":"40","author":"Fujita","year":"2017","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.biopha.2026.119905_bib17","doi-asserted-by":"crossref","first-page":"27613","DOI":"10.1074\/jbc.M201119200","article-title":"Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line","volume":"277","author":"Arico","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119905_bib18","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1158\/0008-5472.CAN-03-2396","article-title":"3-phosphoinositide-dependent protein kinase-1\/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells","volume":"64","author":"Kulp","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119905_bib19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/cbt.4.5.1699","article-title":"Dimethyl-Celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-Inhibitory function, potently mimics the anti-tumor effects of celecoxib on burkitt\u2019s lymphoma in vitro and in vivo","volume":"4","author":"Kardosh","year":"2005","journal-title":"Cancer Biol. & Ther."},{"key":"10.1016\/j.biopha.2026.119905_bib20","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/0008-5472.CAN-03-4063","article-title":"From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors","volume":"64","author":"Zhu","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119905_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1517\/13543784.17.2.197","article-title":"Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs","volume":"17","author":"Sch\u00f6nthal","year":"2008","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2026.119905_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9343(00)00728-2","article-title":"Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors","volume":"110","author":"Buttgereit","year":"2001","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119905_bib23","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1186\/ar1794","article-title":"Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance","volume":"7","author":"Borer","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biopha.2026.119905_bib24","doi-asserted-by":"crossref","first-page":"9348","DOI":"10.1158\/0008-5472.CAN-08-1642","article-title":"OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Species\u2013Related Autophagy in Hepatocellular Carcinoma","volume":"68","author":"Gao","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119905_bib25","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/jcp.25431","article-title":"AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication","volume":"231","author":"Booth","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2026.119905_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.resinv.2026.101429","article-title":"2,5-Dimethylcelecoxib inhibits lung fibrosis in a mouse model of bleomycin-induced pulmonary fibrosis","volume":"64","author":"Morimoto","year":"2026","journal-title":"Respir. Investig."},{"key":"10.1016\/j.biopha.2026.119905_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177184","article-title":"Differentiation-inducing factor-1 inhibits EMT by proteasomal degradation of TAZ and YAP in cervical and colon cancer cell lines","volume":"987","author":"Arioka","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119905_bib28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","article-title":"Simple method of estimating severity of pulmonary fibrosis on a numerical scale","volume":"41","author":"Ashcroft","year":"1988","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.biopha.2026.119905_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2144\/000112729","article-title":"Standardized quantification of pulmonary fibrosis in histological samples","volume":"44","author":"H\u00fcbner","year":"2008","journal-title":"Biotechniques"},{"key":"10.1016\/j.biopha.2026.119905_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115663","article-title":"Promising small molecule anti-fibrotic agents: Newly developed or repositioned drugs targeting myofibroblast transdifferentiation","volume":"214","author":"Ishikane","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119905_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0033-2018","article-title":"Matrix abnormalities in pulmonary fibrosis","volume":"27","author":"Upagupta","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.biopha.2026.119905_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1165\/ajrcmb\/6.2.146","article-title":"Bleomycin regulation of transforming growth factor-beta mRNA in rat lung fibroblasts","volume":"6","author":"Breen","year":"1992","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"Ma","year":"2009","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3349\/ymj.2013.54.2.437","article-title":"Rapamycin inhibits transforming growth factor \u03b21-induced fibrogenesis in primary human lung fibroblasts","volume":"54","author":"Gao","year":"2013","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.biopha.2026.119905_bib35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.279.5351.707","article-title":"Phosphorylation and activation of p70s6k by PDK1","volume":"279","author":"Pullen","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119905_bib36","doi-asserted-by":"crossref","first-page":"30830","DOI":"10.1074\/jbc.M115.703116","article-title":"Transforming Growth Factor \u03b21-induced Apoptosis in Podocytes via the Extracellular Signal-regulated Kinase-Mammalian Target of Rapamycin Complex 1-NADPH Oxidase 4 Axis","volume":"290","author":"Das","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119905_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13435","volume":"56","author":"Tang","year":"2023","journal-title":"Cell. Prolif."},{"key":"10.1016\/j.biopha.2026.119905_bib38","doi-asserted-by":"crossref","first-page":"13374","DOI":"10.1074\/jbc.M409444200","article-title":"The Role of p70S6K in Hepatic Stellate Cell Collagen Gene Expression and Cell Proliferation*","volume":"280","author":"G\u00e4bele","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119905_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrm2125","article-title":"Matrix metalloproteinases and the regulation of tissue remodelling","volume":"8","author":"Page-McCaw","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib40","doi-asserted-by":"crossref","first-page":"13859","DOI":"10.1073\/pnas.95.23.13859","article-title":"NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint","volume":"95","author":"Miagkov","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119905_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249739","article-title":"The roles of matrix metalloproteinases and their inhibitors in human diseases","volume":"21","author":"Cabral-Pacheco","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119905_bib42","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.0022-202X.2004.23487.x","article-title":"Heat shock-induced matrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop","volume":"123","author":"Park","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.biopha.2026.119905_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI12466","article-title":"c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis","volume":"108","author":"Han","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2026.119905_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/biom12060802","article-title":"The translational regulation in mTOR pathway","volume":"12","author":"Yang","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119905_bib45","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1165\/rcmb.2016-0090OC","article-title":"Unique and Redundant Functions of p70 Ribosomal S6 Kinase Isoforms Regulate Mesenchymal Cell Proliferation and Migration in Pulmonary Fibrosis","volume":"55","author":"Madala","year":"2016","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib46","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.bbrc.2018.04.148","article-title":"Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition","volume":"500","author":"Han","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119905_bib47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12931-016-0343-6","article-title":"Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis","volume":"17","author":"Pardo","year":"2016","journal-title":"Respir. Res."},{"key":"10.1016\/j.biopha.2026.119905_bib48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/ar401","article-title":"Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors","volume":"4","author":"Vincenti","year":"2002","journal-title":"Arthritis Res."},{"key":"10.1016\/j.biopha.2026.119905_bib49","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1165\/rcmb.2011-0237OC","article-title":"MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation","volume":"46","author":"Madala","year":"2012","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib50","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12272-025-01566-w","article-title":"Advances in JNK inhibitor development: therapeutic prospects in neurodegenerative diseases and fibrosis","volume":"48","author":"Bhujbal","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.biopha.2026.119905_bib51","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1060028020964451","article-title":"Systematic review and meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the treatment of idiopathic pulmonary fibrosis","volume":"55","author":"Martino","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119905_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2014-0445OC","article-title":"Novel mechanisms for the antifibrotic action of nintedanib","volume":"54","author":"Rangarajan","year":"2016","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib53","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ajrccm\/aamag058","article-title":"Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial","volume":"212","author":"Oldham","year":"2026","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119905_bib54","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","article-title":"Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results","volume":"181","author":"Daniels","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119905_bib55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12890-024-02861-w","article-title":"A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.biopha.2026.119905_bib56","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1165\/rcmb.2017-0419OC","article-title":"Discoidin domain receptor 2 signaling regulates fibroblast apoptosis through PDK1\/Akt","volume":"59","author":"Jia","year":"2018","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib57","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4161\/cbt.9.7.11116","article-title":"OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins","volume":"9","author":"Hamed","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2026.119905_bib58","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4161\/auto.5593","article-title":"PERK-dependent regulation of HSP70 expression and the regulation of autophagy","volume":"4","author":"Park","year":"2008","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2026.119905_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071642","article-title":"Autophagy, Apoptosis, the Unfolded Protein Response, and Lung Function in Idiopathic Pulmonary Fibrosis","volume":"10","author":"Sharma","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119905_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101679","article-title":"Complex interplay between autophagy and oxidative stress in the development of pulmonary disease","volume":"36","author":"Ornatowski","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20240069","article-title":"Caffeic Acid Acts as a Potent Senomorphic and Alleviates Inflammation and Lung Fibrosis by Covalently Targeting Annexin A5 Protein in Mice","volume":"5","author":"Zhu","year":"2025","journal-title":"Exploration"},{"key":"10.1016\/j.biopha.2026.119905_bib62","article-title":"Pulmonary-Targeted Nanoparticles Interrupt the Malignant Mechanical and Biochemical Signaling Crosstalk for Idiopathic Pulmonary Fibrosis Therapy","volume":"13","author":"Li","year":"2026","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.biopha.2026.119905_bib63","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1165\/rcmb.2017-0096ST","article-title":"An official American Thoracic Society Workshop Report: use of animal models for the preclinical assessment of potential therapies for pulmonary fibrosis","volume":"56","author":"Jenkins","year":"2017","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib64","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.biocel.2007.08.011","article-title":"The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?","volume":"40","author":"Moeller","year":"2008","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119905_bib65","article-title":"Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for \"active\" disease","volume":"8","author":"Peng","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119905_bib66","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01105-2019","article-title":"The importance of interventional timing in the bleomycin model of pulmonary fibrosis","volume":"55","author":"Kolb","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2026.119905_bib67","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/a-2649-9402","article-title":"Peeling back the layers of the bleomycin model of lung fibrosis: lessons learned, factors to consider, and future directions","volume":"46","author":"Brazee","year":"2025","journal-title":"Semin. Respir. Crit. Care Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:51:48Z","timestamp":1794743508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":67,"alternative-id":["S0753332226009418"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119905","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OSU-03012 mitigates pulmonary fibrosis by targeting ECM proteins via suppression of S6K-mediated translation and acceleration of MMP-driven clearance","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119905"}}